The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…
Qinlock shows continued promise in patients with GIST
Qinlock (ripretinib) is indicated to treat adult patients with advanced gastrointestinal stromal tumors (GIST). The drug from Qinlock won FDA approval on May 15, 2020. In the Phase 3 INVICTUS study, the drug demonstrated clinical benefits with dose escalation for patients with advanced gastrointestinal stromal tumors with disease progression.